Chronic Hepatitis C with Normal Aminotransferase Levels

Gastroenterology

Volumn 126, Issue 5, 2004, Pages 1409-1415

  Ahmed, Aijaz ^a   Keeffe, Emmet B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; COST EFFECTIVENESS ANALYSIS; ENZYME ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INDIVIDUALIZATION; LIVER BIOPSY; LIVER FUNCTION TEST; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 2142663020     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.02.073     Document Type: Article

References (44)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000;132:296-305.
2. Yen T, Keeffe EB, Ahmed A. Epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003;36:47-53.
3. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
4. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002;36(Suppl): S179-S184.
5. Hoofnagle JH. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. Hepatology 2002;36(Suppl):S3-S20.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
8. Zaman A, Fennerty MB, Keeffe EB. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2003;18:661-670.
9. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652.
10. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK, International Hepatitis Interventional Therapy Group. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003;98:2354-2362.
11. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, DiBisceglie AM. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330-337.
12. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, Sansonetti N, Opolon P. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998;27:1213-1219.
13. Shiffman ML, Stewart CA, Hofmann CM, Contos MJ, Luketic VA, Sterling RK, Sanyal AJ. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000;182:1595-1601.
14. Alter HJ, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, Lau D, Hoofnagle JH. Hepatitis C in asymptomatic blood donors. Hepatology 1997;26(Suppl):29S-33S.
15. Inglesby TV, Rai R, Astemborski J, Gruskin L, Nelson KE, Vlahov D, Thomas DL. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999;29:590-596.
16. Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-1257.
17. Pradat P, Alberti A, Poynard T, Esteban JI, Welland O, Marcellin P, Badalamenti S, Trepo C. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002;36:973-977.
18. Tassopoulos NC. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 1999;31(Suppl):193-196.
19. Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697-698.
20. Van Thiel DH, Caraceni P, Molloy PJ, Hassanein T, Kania RJ, Gurakar A, Friedlander L. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy. J Hepatol 1995;23:503-508.
21. Gholson CF, Morgan K, Catinis G, Favrot D, Taylor B, Gonzalez E, Balart L. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 1996;92:1788-1792.
22. Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara L. Persistent hepatitis C viraemia without liver disease. Lancet 1993;341:464-465.
23. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C-infected patients with persistently normal alanine aminotransferase levels in the southwestern United States. Hepatology 1999;30:1307-1311.
24. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-872.
25. Stanley AJ, Haydon GH, Piris J, Jarvis LM, Hayes PC. Assessment of liver histology in patients with hepatitis C and normal transaminase levels. Eur J Gastroenterol Hepatol 1996;8:869-872.
26. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease 1997;26(Suppl):15S-20S.
27. Kronenberger B, Ruster B, Lee JH, Sarrazin C, Roth WK, Herrmann G, Zeuzem S. Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal amino-transferase levels. J Hepatol 2000;33:640-647.
28. Nutt AK, Hassan HA, Lindsey J, Lamps LW, Raufman JP. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine amino-transferase levels. Am J Med 2000;109:62-64.
29. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
30. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
31. Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C-a study of 527 patients at one establishment. J Viral Hepat 2000;7:268-275.
32. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
33. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870.
34. National Institute of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(Suppl):S2-S10.
35. Consensus Panel: EASL international consensus conference on hepatitis C: Paris, 26-28 February 1999. Consensus statement. J Hepatol 1999;30:956-961.
36. Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht JK. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000;32:400-404.
37. Lee SS, Sherman M. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J Viral Hepat 2001;8:202-205.
38. DiBisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001;33:704-707.
39. Jacobson IM, Russo MW, Lebovics E, Esposito S, Tobias H, Klion F, Brown RS Jr, Dieterich D, Brass C, and The NY Normal ALT Study Groupet. Interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal ALT: final results. Gastroenterology 2002;122:A-627.
40. Sponseller C, Koehler KM, Hoffman JA, Strinko JM, Bacon BR. Use of interferon α-2b and ribavirin for treatment of patients with chronic hepatitis C and normal ALT levels (abstr). Hepatology 2002;36:579A.
41. Zeuzem S, Diago M, Gane E, Reddy R, Pockros P, Farci P, Gitlin N, Lamour F, Lardelli P, Shiffman M. International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40 KD) (PEGASYS®) and ribavirin (COPEGUS®) (abstr). Hepatology 2003;38:208A.
42. Shiffman M, Diago M, Tran A, Pockros P, Reindollar R, Prati D, Lamour F, Lardelli P, Zeuzem S. Natural history of patients with chronic hepatitis C and persistently normal alanine aminotransferase levels: data from the multinational Pegasys® study (NR 16071) (abstr). Hepatology 2003;38:434A.
43. Wagner MV, Lee JH, Friedi R, Wolfgang J, Kronenberger B, Sarrazin C, Zeuzem S. Impaired quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels. (abstr). Hepatology 2003;38:454A.
44. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000;133:665-675.